Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer.

Winnie Wing Chuen Lam, Kelvin Siu Hoong Loke, Hoi Yin Loi, Ajit Kumar Padhy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pancreatic involvement by metastasis from other primaries is rare and accounts for approximately 2% to 4% of pancreatic tumors. In this article, we describe FDG-avid pancreatic involvement in a patient with diagnosis of breast cancer. We conclude that FDG PET can be a convenient noninvasive method of early detection of recurrence and in monitoring metastatic disease during follow-up in such patients. A positive FDG PET warrants histopathologic correlation for appropriate treatment.

Original languageEnglish
Pages (from-to)479-480
Number of pages2
JournalClinical Nuclear Medicine
Volume36
Issue number6
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Recurrence
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Lam, W. W. C., Loke, K. S. H., Loi, H. Y., & Padhy, A. K. (2011). Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer. Clinical Nuclear Medicine, 36(6), 479-480.

Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer. / Lam, Winnie Wing Chuen; Loke, Kelvin Siu Hoong; Loi, Hoi Yin; Padhy, Ajit Kumar.

In: Clinical Nuclear Medicine, Vol. 36, No. 6, 06.2011, p. 479-480.

Research output: Contribution to journalArticle

Lam, WWC, Loke, KSH, Loi, HY & Padhy, AK 2011, 'Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer.', Clinical Nuclear Medicine, vol. 36, no. 6, pp. 479-480.
Lam, Winnie Wing Chuen ; Loke, Kelvin Siu Hoong ; Loi, Hoi Yin ; Padhy, Ajit Kumar. / Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer. In: Clinical Nuclear Medicine. 2011 ; Vol. 36, No. 6. pp. 479-480.
@article{dc990027038944dfa9d0b10c83373c5d,
title = "Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer.",
abstract = "Pancreatic involvement by metastasis from other primaries is rare and accounts for approximately 2{\%} to 4{\%} of pancreatic tumors. In this article, we describe FDG-avid pancreatic involvement in a patient with diagnosis of breast cancer. We conclude that FDG PET can be a convenient noninvasive method of early detection of recurrence and in monitoring metastatic disease during follow-up in such patients. A positive FDG PET warrants histopathologic correlation for appropriate treatment.",
author = "Lam, {Winnie Wing Chuen} and Loke, {Kelvin Siu Hoong} and Loi, {Hoi Yin} and Padhy, {Ajit Kumar}",
year = "2011",
month = "6",
language = "English",
volume = "36",
pages = "479--480",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer.

AU - Lam, Winnie Wing Chuen

AU - Loke, Kelvin Siu Hoong

AU - Loi, Hoi Yin

AU - Padhy, Ajit Kumar

PY - 2011/6

Y1 - 2011/6

N2 - Pancreatic involvement by metastasis from other primaries is rare and accounts for approximately 2% to 4% of pancreatic tumors. In this article, we describe FDG-avid pancreatic involvement in a patient with diagnosis of breast cancer. We conclude that FDG PET can be a convenient noninvasive method of early detection of recurrence and in monitoring metastatic disease during follow-up in such patients. A positive FDG PET warrants histopathologic correlation for appropriate treatment.

AB - Pancreatic involvement by metastasis from other primaries is rare and accounts for approximately 2% to 4% of pancreatic tumors. In this article, we describe FDG-avid pancreatic involvement in a patient with diagnosis of breast cancer. We conclude that FDG PET can be a convenient noninvasive method of early detection of recurrence and in monitoring metastatic disease during follow-up in such patients. A positive FDG PET warrants histopathologic correlation for appropriate treatment.

UR - http://www.scopus.com/inward/record.url?scp=80052061413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052061413&partnerID=8YFLogxK

M3 - Article

C2 - 21552032

AN - SCOPUS:80052061413

VL - 36

SP - 479

EP - 480

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 6

ER -